Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group

Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of EzutromidAllows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD,...
February 26, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc : Research Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc('Summit', or 'the...
February 26, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD

MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle HealthData Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom,...
February 23, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit", or the...
February 09, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics to Participate in Upcoming Investor Conferences

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit", or the...
January 25, 2018 07:05 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc('Summit', or...
January 25, 2018 07:00 ET | Source: Summit Therapeutics plc

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...
January 09, 2018 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics to Present at the Biotech Showcase

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit", or the...
December 23, 2017 16:01 ET | Source: Summit Therapeutics plc

Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ('Summit' or the...
December 23, 2017 16:00 ET | Source: Summit Therapeutics plc

Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd

Positions Summit as a Leader in Research & Development of New Classes of AntibioticsEnhances Summit’s Broader Business in Rare and Infectious DiseasesSupports Mission to Discover and Develop...